Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9547584rdf:typepubmed:Citationlld:pubmed
pubmed-article:9547584lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:9547584lifeskim:mentionsumls-concept:C0014597lld:lifeskim
pubmed-article:9547584lifeskim:mentionsumls-concept:C0929301lld:lifeskim
pubmed-article:9547584lifeskim:mentionsumls-concept:C0006141lld:lifeskim
pubmed-article:9547584lifeskim:mentionsumls-concept:C0205160lld:lifeskim
pubmed-article:9547584lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:9547584lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:9547584lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:9547584pubmed:dateCreated1998-5-28lld:pubmed
pubmed-article:9547584pubmed:abstractTextDeregulated expression of Ras and myc oncogenes confers neoplastic transformation in non-tumorigenic mammary epithelial cells. Down-regulation of perturbed biomarkers prior to tumorigenesis may provide a means of effective chemoprevention. In vitro experiments were designed to i) identify specific molecular, endocrine and cellular biomarkers as quantitative end points for preneoplastic transformation, and ii) utilize these end points to evaluate chemopreventive efficacy of selected naturally-occurring and synthetic tumor inhibitors. Stable Ras and myc transfectants exhibited persistent expression of oncogene specific mRNA transcripts, altered estradiol biotransformation and enhanced anchorage-independent growth in vitro prior to tumorigenesis in vivo. Treatment of the transfectants with omega-3-fatty acid, indole-3-carbinol and tamoxifen individually suppressed the perturbed molecular, endocrine and cellular biomarkers in vitro. Thus, suppressed oncogene expression and altered estrogen metabolism may be important determinants for antiproliferative mechanisms in mammary tumor inhibition, providing useful end points for chemopreventive intervention of preneoplasia.lld:pubmed
pubmed-article:9547584pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9547584pubmed:languageenglld:pubmed
pubmed-article:9547584pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9547584pubmed:citationSubsetIMlld:pubmed
pubmed-article:9547584pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9547584pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9547584pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9547584pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9547584pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9547584pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9547584pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9547584pubmed:statusMEDLINElld:pubmed
pubmed-article:9547584pubmed:issn0065-2598lld:pubmed
pubmed-article:9547584pubmed:authorpubmed-author:InoueSSlld:pubmed
pubmed-article:9547584pubmed:authorpubmed-author:OsborneM PMPlld:pubmed
pubmed-article:9547584pubmed:authorpubmed-author:BradlowH LHLlld:pubmed
pubmed-article:9547584pubmed:authorpubmed-author:TelangN TNTlld:pubmed
pubmed-article:9547584pubmed:issnTypePrintlld:pubmed
pubmed-article:9547584pubmed:volume400Alld:pubmed
pubmed-article:9547584pubmed:ownerNLMlld:pubmed
pubmed-article:9547584pubmed:authorsCompleteYlld:pubmed
pubmed-article:9547584pubmed:pagination409-18lld:pubmed
pubmed-article:9547584pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:meshHeadingpubmed-meshheading:9547584-...lld:pubmed
pubmed-article:9547584pubmed:year1997lld:pubmed
pubmed-article:9547584pubmed:articleTitleNegative growth regulation of oncogene-transformed mammary epithelial cells by tumor inhibitors.lld:pubmed
pubmed-article:9547584pubmed:affiliationStrang-Cornell Cancer Research Laboratory, Cornell University Medical College, New York, New York, USA.lld:pubmed
pubmed-article:9547584pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9547584pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9547584pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed